{"name":"Zeria Pharmaceutical","slug":"zeria-pharmaceutical","ticker":"","exchange":"","domain":"zeria.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Rabeprazole Sodium 20mg","genericName":"Rabeprazole Sodium 20mg","slug":"rabeprazole-sodium-20mg","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Rabeprazole Sodium 20mg","genericName":"Rabeprazole Sodium 20mg","slug":"rabeprazole-sodium-20mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilAJBVV95cUxNaC0xWjQxemp6SjQ4ZkFIRXZmTk95R1N6ZVdNajZyNkhsM042NUdqRnhsMUpfZ2JxVXZCek9RRkNjQ3FCZGN6NENnSWk3UDRYMW1UUDdvdTBDRHc1b0s1WURGak8xa3dmWjViYk5pT1N4amRYdDlEWVFkNmFJekE1ZVpKamZfeGk0WG9pb09BWFFLb1lwQVlxaFhoVl9tVmVnYzFEYXBualdZazROeEtVTFNXTzRPZ1VQb1pyRnJPX0NvUWRZTXI1U3VWMEhVMDhfcndrYm1qdTd0TFB3bjhrcXFZd2ZVNXo5ZHpCUUFZRzBUUWhOVGNhamVuX2VxRDh6STdHOTRfWGVaV1psUnpwTnJPLU0?oc=5","date":"2026-01-19","type":"pipeline","source":"prnewswire.com","summary":"Underactive Bladder Syndrome Market to Observe Stunning Growth at a CAGR of 22.1% During the Forecast Period (2025-2034) | DelveInsight - prnewswire.com","headline":"Underactive Bladder Syndrome Market to Observe Stunning Growth at a CAGR of 22.1% During the Forecast Period (2025-2034)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-11","type":"pipeline","source":"ETLegalWorld.com","summary":"IPIC Series: Global Pharma Reworks IP Strategy Amid India’s Anti-Evergreening Push - ETLegalWorld.com","headline":"IPIC Series: Global Pharma Reworks IP Strategy Amid India’s Anti-Evergreening Push","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTE1kNThzU1RrU09sakFCdlJaOXVVZnZhcjg2OXpIajhaMEk4N25DaF95YXo0Tk9ZakdYRl92bnBLcXZmdkZJaG1YZzVCSFVmSFRmdHpybHhTMEdVQTJQZFNDb1dXYzExZw?oc=5","date":"2025-10-30","type":"pipeline","source":"MedPage Today","summary":"Novel Oral miR-124 Enhancer Improves Remission in Refractory UC - MedPage Today","headline":"Novel Oral miR-124 Enhancer Improves Remission in Refractory UC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxQRkRTT1pLbHZGMlNGMDlXNVFNTVJpanhhYUx4a2RNcG1adTBxanBDZWJrV0g5ZDI0VWFvOFJyXy1XMzJXODY5U1dSc3ZZaWFMTFZrb2Y4SFdyWi1UVl9fSEF3ei16UklVUjFsa1REV3p1MDRCVXI1X0FuejZXQ3RmWm9XenZSZVJTdUMyUFp0UU10QnJkenUyMjNJQU9PS1FpWFdpbm9iYi1IaERaNHRMWldYYzJjT0s1MTRzZnVocy1hdEFBb2ZGSDhNVnRENzJHZmlaMlB2Y1gtTjZVRElvMmxsNUdJMmY2a3Y4MzVlTdIB7wFBVV95cUxQRkRTT1pLbHZGMlNGMDlXNVFNTVJpanhhYUx4a2RNcG1adTBxanBDZWJrV0g5ZDI0VWFvOFJyXy1XMzJXODY5U1dSc3ZZaWFMTFZrb2Y4SFdyWi1UVl9fSEF3ei16UklVUjFsa1REV3p1MDRCVXI1X0FuejZXQ3RmWm9XenZSZVJTdUMyUFp0UU10QnJkenUyMjNJQU9PS1FpWFdpbm9iYi1IaERaNHRMWldYYzJjT0s1MTRzZnVocy1hdEFBb2ZGSDhNVnRENzJHZmlaMlB2Y1gtTjZVRElvMmxsNUdJMmY2a3Y4MzVlTQ?oc=5","date":"2024-12-03","type":"pipeline","source":"simplywall.st","summary":"Zeria Pharmaceutical (TSE:4559) Will Pay A Dividend Of ¥23.00 - simplywall.st","headline":"Zeria Pharmaceutical (TSE:4559) Will Pay A Dividend Of ¥23.00","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxPd0xwS1JEejE3dzBYczBlVGZzaGI3NFItakFfUmtsSlF0M0hSd0ZoM0xYY3N6R285ajNvdGN3aFJaQnNFMjVraFBuOW9oWi16NEljbGRxSWFzRXNRb193X1ZQX0szQ3M0NExRVVpiaEE0Q1NOdTFwTHV0TE14UEhneHA3V1duQzZEQ0pLTlEwMGNSODlFYmdQbE9JTEZ3TDc0c3V0QXlVemlTakk4emlqSHBMZm1NNF9IdS01eW9leDRWTkMwNzB5YXJBMy14N3ZrOXBaMXFZaDk?oc=5","date":"2024-09-25","type":"regulatory","source":"BioPharma APAC","summary":"Veltassa® Secures Approval in Japan for Hyperkalemia Management in CKD and Heart Failure Patients - BioPharma APAC","headline":"Veltassa® Secures Approval in Japan for Hyperkalemia Management in CKD and Heart Failure Patients","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE5ZWFpzVUtDMEtpSUlVUEw4cFJ6enZsamdBQzZfX3AxenRFYS0yUkRZbXdQaW90TXV1WmdKZHlSUTlpNVFjelI0dlk2enQ3V1ZEbDBBbGZDT0Z4RHVYSC1kVnRCSHFKUlRC?oc=5","date":"2022-06-23","type":"pipeline","source":"Wiley Online Library","summary":"Safety and efficacy of long-term tofacitinib treatment in East Asian patients with ulcerative colitis in OCTAVE Open - Wiley Online Library","headline":"Safety and efficacy of long-term tofacitinib treatment in East Asian patients with ulcerative colitis in OCTAVE Open","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAJBVV95cUxPN1RrLTVDcXY5NHF1aWs4ZUJHZjUxcHRPZ3BxQ1llclFLT0hPNWpxeEd1OC1VOE5TTnZIZ3BDemhSOUdfeGtPXzhXaE1wSXRTcHRzNEI5VVdtODBFdEk1em5meXRnNGE4Q2pUWkRMN1A3RU1DeUFxT2l2OF9TWUFVZzJhdnZ4NkhOOXpHOHpOZk51emV3WTRMVEdvRk9kNi12N0s4UGtuTVJvTmlEZmJBNkdKSjdwYjFLaFFFMW02c0JqVmRWYUxmZk5wUUpCclhnaGZ3aGoyR0t2OEZlVHVXcGpCQW5CQUxfcldncE50R245TjZ2azhqcGNHSmpCeVk4am9TdTA1Q3FHUXVGRElLdWFTamEzNHk4cURReElZdXhaQ1ha?oc=5","date":"2021-12-07","type":"pipeline","source":"businesswire.com","summary":"(fidaxomicin) is recommended for the treatment of Clostridioides difficile infection (CDI) by ESCMID - businesswire.com","headline":"(fidaxomicin) is recommended for the treatment of Clostridioides difficile infection (CDI) by ESCMID","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQbENuTTZDQjR1STB0ZTZqQ19ycTdJR2U4U0VEdEhlX25xQTJ4M2FqYTdmaUdOeHRvandTbDI1UWR2ZU9uclI1LVFhMTV5a1BtMGNYUXFtcHA4X0QzTVIybktzMUdpeU9RRFhDdV9OWXdkOEtsRkdMbVlNMVlHRkdUdDdiTFJ3alZxSmZ5VGdNYTgyLUtaX2hCdEthZ1dzdjdFVVdiazJUMjlMd1NYWXg4?oc=5","date":"2018-09-03","type":"pipeline","source":"The Pharma Letter","summary":"Karima Boubekeur leaves AstraZeneca to head innovation at Tillotts - The Pharma Letter","headline":"Karima Boubekeur leaves AstraZeneca to head innovation at Tillotts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQM1JubW1NS2NMT01hUlgwWUZNZ0c0d3NTaXluX2dDYkN4dWU1Y09XMzdjOGczTTF0MTFaTHdKZDBrZ2phbXZfUDhhSWkzbFg0S3Q4X085aDQ4QTJxYUFEdDhKcEZRMGJ1NFE0ZFU2eGkxUzdaakw3aktJSkJnQWVMcS12YlR6X0pFMTN2aDJiZGNHaHlIaFE5QTRabXVLTzRyNWVHOUpCb2tlWXFW?oc=5","date":"2017-10-18","type":"patent","source":"Center for Biosimilars","summary":"Eye on Pharma: Nichi-Iko Seeks Interchangeable Designation for NI-071 - Center for Biosimilars","headline":"Eye on Pharma: Nichi-Iko Seeks Interchangeable Designation for NI-071","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxONFQxenU1REJ6WW9RYkZoa2FFRS1uWWo4SHFaNU5xX3ZFVVdpeEY2dE9SUFVQb2VOQmZ6VWpPM3FOZ3g0dFRfUWxnUjVTX1E2cHRMaXlpb1FxWk11QmU3T0hhNzZFYXhObHF1d2pjZFc5ZFlJcG1HLVlKT2lhN083alNVcWg5TlpNWmZ2VzNobHgyWVFwY1BJOFhtbTNDVEl2ZnY4MDdoSWtYUnhQMDcybjhlLUxmUEF5RzhJMHB5aFU2UWs4cGkyeUlWTTlYR2o3NENn?oc=5","date":"2015-07-17","type":"pipeline","source":"AstraZeneca","summary":"AstraZeneca completes agreement with Tillotts Pharma for Entocort - AstraZeneca","headline":"AstraZeneca completes agreement with Tillotts Pharma for Entocort","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxOaGNJbjhNdUFDTEEzdUZ6Q19YNUx0c1d3RThua3ByTU0zWUs2Z1BIR0RXc3NQaUlZWV92X3ItWkQ0UDBYNWR5ZktXR1JxOGNVdG1FMWoteVp2bW01UEtNYVY5N09oLTZaOW5TcVF6SmpOVjhTallWNTMzM3U4eXo4ZlBQa1JKOVcxQ0ZXSWg1LU42SmZFZFJRUnFuU0pHNkVtaUFGcnh2enFsOEJma1VqdzFBdkUwM0hwekx6WjNBOWo3aG5WTXNF?oc=5","date":"2015-07-09","type":"pipeline","source":"AstraZeneca","summary":"AstraZeneca sharpens focus on main therapy areas through agreement with gastroenterology specialist Tillotts Pharma for Entocort - AstraZeneca","headline":"AstraZeneca sharpens focus on main therapy areas through agreement with gastroenterology specialist Tillotts Pharma for ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxONlNiSmIySEVSMHpLY2ExMkp3UURLemlfOFQzRXJZaUJ1REF3Q3dYRFV3a0YxNFZsSjNXNHBvd0ZkaGJaXzBVajR5dzV6Y2xtUjZLZy1kODJhUllydm5rNkpvallETV9Ua19lYzRjVU1XczBFNThIQUZfYWdKRzhXZGxacDBGTkpaN0RwN1N2bHVuRVNMLTc2YQ?oc=5","date":"2013-04-01","type":"pipeline","source":"BioSpectrum Asia","summary":"Zeria gets nod for Acofide Tablets in Japan - BioSpectrum Asia","headline":"Zeria gets nod for Acofide Tablets in Japan","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}